Injections of a protein found in the cells of humans prolong the life of laboratory mice by delaying the onset of amyotrophic lateral sclerosis (ALS), US researchers said in a study published Tuesday.
The treatment with the Hsp70 protein prolonged the life of diseased mice by 10 percent and delayed the onset of ALS longer than Riluzole, the only US Food and Drug Administration approved treatment for the incurable degenerative neurological disorder also known as Lou Gehrig's disease.
Know Your Nervous System
The Central nervous system consists of the brain, the spinal cord, and the body's nerve network. This complex system is based on one kind of cell the neurons.
Advertisement
Wake Forest University researchers in North Carolina said Hsp70 could lead to new approaches in the treatment of ALS, but said that it has yet to be approved for clinical trials with humans.
Lead researcher David Gifondorwa said the discovery added one more piece of the puzzle behind the causes of ALS and that it could one day be part of a cocktail of remedies to deal with this fatal disease.
![New Study Finds Biological Pathways for ALS Progression]( "New Study Finds Biological Pathways for ALS Progression")
A new study has discovered biological pathways for the progression of sporadic amyotrophic lateral sclerosis (ALS).
In the study published in the Journal of Neuroscience, researchers used genetically modified laboratory mice to carry the faulty gene that causes 2.0-3.0 percent of ALS cases in humans.
The animals were divided into three groups and treated respectively with a placebo, Riluzole and Hsp70.
The Hsp70 protein was extracted by thermal shock, a process by which cells eject a substance to protect themselves from a sudden increase of temperature.
Source: AFP
LIN/P
New Study Finds Biological Pathways for ALS Progression
A new study has discovered biological pathways for the progression of sporadic amyotrophic lateral sclerosis (ALS).
Advertisement
In the study published in the Journal of Neuroscience, researchers used genetically modified laboratory mice to carry the faulty gene that causes 2.0-3.0 percent of ALS cases in humans.
The animals were divided into three groups and treated respectively with a placebo, Riluzole and Hsp70.
The Hsp70 protein was extracted by thermal shock, a process by which cells eject a substance to protect themselves from a sudden increase of temperature.
Source: AFP
LIN/P
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Research News
The International Space Station will be used to carry out experiments seeking to improve understanding of incurable child brain tumors and the muscle aging process.
How many people in the UK have misophonia? In a representative sample study, most people had at least some irritation upon hearing trigger sounds.
Routine eye-checkups and mass screenings enable early diagnosis and treatment of glaucoma. Late-stage glaucoma diagnosis leads to blindness.
Brain plasticity following blindness leads to superior ability in sensing signals from the heart, which has implications for bodily awareness and emotional processing.
A group of scientists were awarded £1.3 million to create a new “point of care testing” kit that detects Alzheimer's disease biomarkers.